Latest Amyloid Stories
Up to 92 percent reduction in transthyretin protein in patients with familial amyloid polyneuropathy CARLSBAD, Calif., April 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Issues Concerning Athletes proudly announces its hosting of the #Speedheals Celebrity Bartender Night, a benefit supporting the fight against Amyloidosis and support for children enduring cancer
CAMBRIDGE, Mass., March 16, 2015 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc., today announced that Richard Fisher, PhD, the Company's Chief Scientific Officer, will present at the 12(th)
--Funds Will Advance Breakthrough Drug Candidate NPT088 into the Clinic-- CAMBRIDGE, Mass., Jan.
CAMBRIDGE, Mass., Nov.
Dr. Hefti to Lead All Clinical Development Efforts and Strategic Initiatives CAMBRIDGE, Mass., Nov.
New Study Shows Link between Plaques and Tangles/Could Open Door to Therapeutic Target Boston (PRWEB) October 13, 2014 In what is being hailed by scientists
- LUNAR-101, an UNA(TM) oligomer therapeutic for transthyretin-mediated familial amyloid cardiomyopathy (TTR-FAC), exhibited in non-human primates TTR reduction greater than 90% with a single low dose
Spider silk is an impressive material; lightweight and stretchy yet stronger than steel. But the challenge that spiders face to produce this substance is even more formidable.
- An armed gangster.